Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Sleight

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Circulation|September 23, 2009
Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular DiseasePaolo Verdecchia, Peter Sleight, Giuseppe Mancia, et al.
Hypertension (Dallas, Tex. : 1979)|October 17, 2012
Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)Giuseppe Mancia, Gianfranco Parati, Grzegorz Bilo, et al.
Journal of Hypertension|April 13, 2012
Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studiesPaolo Verdecchia, Gilles Dagenais, Jeff Healey, et al.
European Heart Journal|March 17, 2012
Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?Faiez Zannad, Wendy Gattis Stough, Stuart J Pocock, et al.
Journal of the American College of Cardiology|February 7, 2006
Predictors of adverse outcome among patients with hypertension and coronary artery diseaseCarl J Pepine, Peter R Kowey, Stuart Kupfer, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|August 30, 2008
Cardiovascular protection for all individuals at high risk: evidence-based best practiceGeorge Bakris, Michael Böhm, Gilles Dagenais, et al.
Hypertension (Dallas, Tex. : 1979)|January 14, 2015
Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular riskMichael Böhm, Helmut Schumacher, Darryl Leong, et al.
JAMA|April 24, 2003
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trialHenry R Black, William J Elliott, Gregory Grandits, et al.
Lancet (London, England)|January 13, 2015
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials, Jordan Fulcher, Rachel O'Connell, et al.
Journal of Hypertension|April 19, 2005
Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical regionHenry R Black, William J Elliott, Gregory Grandits, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Circulation|September 23, 2009
Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular DiseasePaolo Verdecchia, Peter Sleight, Giuseppe Mancia, et al.
Hypertension (Dallas, Tex. : 1979)|October 17, 2012
Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)Giuseppe Mancia, Gianfranco Parati, Grzegorz Bilo, et al.
Journal of Hypertension|April 13, 2012
Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studiesPaolo Verdecchia, Gilles Dagenais, Jeff Healey, et al.
European Heart Journal|March 17, 2012
Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?Faiez Zannad, Wendy Gattis Stough, Stuart J Pocock, et al.
Journal of the American College of Cardiology|February 7, 2006
Predictors of adverse outcome among patients with hypertension and coronary artery diseaseCarl J Pepine, Peter R Kowey, Stuart Kupfer, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|August 30, 2008
Cardiovascular protection for all individuals at high risk: evidence-based best practiceGeorge Bakris, Michael Böhm, Gilles Dagenais, et al.
Hypertension (Dallas, Tex. : 1979)|January 14, 2015
Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular riskMichael Böhm, Helmut Schumacher, Darryl Leong, et al.
JAMA|April 24, 2003
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trialHenry R Black, William J Elliott, Gregory Grandits, et al.
Lancet (London, England)|January 13, 2015
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials, Jordan Fulcher, Rachel O'Connell, et al.
Journal of Hypertension|April 19, 2005
Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical regionHenry R Black, William J Elliott, Gregory Grandits, et al.
Pageof 9